September 26, 2016 08:56 AM EDT
R&D

Ar­ray Bio surges on pos­i­tive re­sults for first stage of melanoma com­bo PhI­II

John Carroll

Editor & Founder

Shares of Ar­ray Bio­phar­ma $AR­RY surged 29% Mon­day morn­ing af­ter the Boul­der, CO-based biotech and its part­ners at Pierre Fab­re in France said that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times